App-Quantinova.ai

Pituitary carcinoma: a case of dramatic response to immunotherapy (ipilimumab + nivolumab) after failure with temozolomide

Sanjit Shah - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pituitary adenomas

Nivolumab

P-ERK ASSOCIATION WITH OVERALL SURVIVAL IN RECURRENT GBM PATIENTS TREATED WITH INTRACEREBRAL ADMINISTRATION OF PD-1 AND CTLA-4 BLOCKING ANTIBODIES

Victor Arrieta - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

REAL WORLD CLINICAL OUTCOMES OF PATIENTS WITH DIFFUSE MIDLINE GLIOMA IN A LONGITUDINAL OUTCOMES REGISTRY

Timothy Stuhlmiller - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

Nivolumab

NEURONAL INTERMEDIATE FILAMENT (NIF) ANTIBODY POSITIVE PARANEOPLASTIC SYNDROME IN A PATIENT WITH METASTATIC NEUROENDOCRINE PANCREATIC CARCINOMA AND TREATMENT WITH IPILIMUMAB/NIVOLUMAB

Karla Mora Rodriguez - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Metastatic pancreatic adenocarcinoma

Nivolumab

EVALUATING THE ASSOCIATION BETWEEN PERIPHERAL BLOOD IMMUNOLOGIC RESPONSE AND THERAPEUTIC RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA AND GLIOSARCOMA

Matthew Watowich - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Nivolumab

A PHASE I CLINICAL TRIAL ON THE INTRACRANIAL ADMINISTRATION OF INCREASING DOSES OF IPILIMUMAB PLUS FIXED DOSE NIVOLUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGB)

Wietse Geens - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Nivolumab

EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)

David A Reardon - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Nivolumab

RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT

Manmeet Ahluwalia - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Nivolumab

NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA

Hao-Wen Sim - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Nivolumab

IMMUNOTHERAPY ADMINISTRATION RATES IN PATIENTS WITH BRAIN METASTASES: IMPACT OF END STAGE RENAL DISEASE AND DIALYSIS

Angel Baroz - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

Nivolumab

IMPACT OF IMMUNOTHERAPY ON PREVALENCE OF BRAIN METASTASES IN MALIGNANT MELANOMA: A REAL-WORLD POPULATION-LEVEL ANALYSIS

Debarati Bhanja - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Nivolumab

Phase I study of the nivolumab combined with IFN-B in patients with advanced melanoma

T. Fujimura - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Nivolumab

Analysis of immune-related adverse events correlated with good prognosis in melanoma treatment and fluctuating blood factors

K. Nakamura - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Enterocolitis

Nivolumab

Nivolumab plus PAI-1 inhibitor combined therapy for unresectable advanced melanoma: Phase II clinical trial

T. Fujimura - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Nivolumab

Longer recurrence free survival (RFS) in germline pathogenic variant (gPV) positive patients with melanoma on adjuvant checkpoint immunotherapy (IO)

A. Shen - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lynch syndrome

Nivolumab

LAG-3 expression in advanced basal cell carcinoma (BCC) and tumor regression following combined PD-1/LAG-3 blockade

J.S. Deutsch - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Basal cell carcinoma

Nivolumab

Current treatment options for patients with unresectable cutaneous melanoma

S. Shimon - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Dyspnea

Nivolumab

Desmoglein 2 promotes tumor development through miR-146a/IRAK1/IL-8 signaling axis

B.L. Hill - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Nivolumab

JAK-STAT activation in anti-PD-1 therapy-associated granuloma annulare

R. Choi - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Nivolumab

Presentation and management of immune checkpoint inhibitors-induced psoriasis: A single-center Experience

A. Jfri - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Nivolumab

Filters

2342 Abstracts